Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
62
CAPR Quote, Financials, Valuation and Earnings
Last price:
$28.50
Seasonality move
:
-8.11%
Day range:
$25.07 - $29.28
52-week range:
$4.30 - $40.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
118.88x
P/B ratio:
18.91x
Volume:
2.4M
Avg. volume:
1.2M
1-year change:
93.17%
Market cap:
$1.6B
Revenue:
$22.3M
EPS (TTM):
-$1.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CAPR
Capricor Therapeutics, Inc.
|
-- | -$0.55 | -100% | -7.2% | $50.80 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$231M | $1.98 | 11.21% | 141.43% | $110.50 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.43 | -2.86% | -65.51% | $14.00 |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CAPR
Capricor Therapeutics, Inc.
|
$29.15 | $50.80 | $1.6B | -- | $0.00 | 0% | 118.88x |
|
AGEN
Agenus, Inc.
|
$3.21 | $12.33 | $116M | -- | $0.00 | 0% | 0.81x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$78.10 | $110.50 | $1.8B | 47.90x | $0.00 | 0% | 1.91x |
|
CRIS
Curis, Inc.
|
$1.14 | $14.00 | $14.7M | -- | $0.00 | 0% | 1.09x |
|
LADX
LadRx Corp.
|
$0.10 | -- | $51.2K | 0.84x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.29 | $5.50 | $40.2M | -- | $0.00 | 0% | 4.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CAPR
Capricor Therapeutics, Inc.
|
17.61% | -4.224 | 5.44% | 3.50x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.779 | 30.7% | 2.40x |
|
CRIS
Curis, Inc.
|
192.35% | 2.868 | 144.76% | 0.62x |
|
LADX
LadRx Corp.
|
-- | 2.863 | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CAPR
Capricor Therapeutics, Inc.
|
-$494.7K | -$26.3M | -72.3% | -77.32% | -69.16% | -$23.7M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Capricor Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CAPR or AGEN?
Agenus, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -116.82%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About CAPR or AGEN?
Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 74.27%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 284.22%. Given that Agenus, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Agenus, Inc. is more attractive than Capricor Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CAPRCapricor Therapeutics, Inc.8 0 0 AGENAgenus, Inc.2 1 0 -
Is CAPR or AGEN More Risky?
Capricor Therapeutics, Inc. has a beta of 0.377, which suggesting that the stock is 62.266% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock CAPR or AGEN?
Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CAPR or AGEN?
Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 118.88x versus 0.81x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CAPRCapricor Therapeutics, Inc.118.88x -- -- -$24.6M AGENAgenus, Inc.0.81x -- $30.2M $63.9M
-
Which has Higher Returns CAPR or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of 10.59%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About CAPR or ANIP?
Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 74.27%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $110.50 which suggests that it could grow by 41.49%. Given that Capricor Therapeutics, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Capricor Therapeutics, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CAPRCapricor Therapeutics, Inc.8 0 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is CAPR or ANIP More Risky?
Capricor Therapeutics, Inc. has a beta of 0.377, which suggesting that the stock is 62.266% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.500, suggesting its less volatile than the S&P 500 by 50.037%.
-
Which is a Better Dividend Stock CAPR or ANIP?
Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CAPR or ANIP?
Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 47.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 118.88x versus 1.91x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CAPRCapricor Therapeutics, Inc.118.88x -- -- -$24.6M ANIPANI Pharmaceuticals, Inc.1.91x 47.90x $227.8M $24.1M
-
Which has Higher Returns CAPR or CRIS?
Curis, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -243.36%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About CAPR or CRIS?
Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 74.27%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1128.07%. Given that Curis, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Curis, Inc. is more attractive than Capricor Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CAPRCapricor Therapeutics, Inc.8 0 0 CRISCuris, Inc.4 0 0 -
Is CAPR or CRIS More Risky?
Capricor Therapeutics, Inc. has a beta of 0.377, which suggesting that the stock is 62.266% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.
-
Which is a Better Dividend Stock CAPR or CRIS?
Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CAPR or CRIS?
Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 118.88x versus 1.09x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CAPRCapricor Therapeutics, Inc.118.88x -- -- -$24.6M CRISCuris, Inc.1.09x -- $3.2M -$7.7M
-
Which has Higher Returns CAPR or LADX?
LadRx Corp. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of --. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat LadRx Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M LADXLadRx Corp.-- -$1.45 -- -
What do Analysts Say About CAPR or LADX?
Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 74.27%. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 434682.61%. Given that LadRx Corp. has higher upside potential than Capricor Therapeutics, Inc., analysts believe LadRx Corp. is more attractive than Capricor Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CAPRCapricor Therapeutics, Inc.8 0 0 LADXLadRx Corp.0 0 0 -
Is CAPR or LADX More Risky?
Capricor Therapeutics, Inc. has a beta of 0.377, which suggesting that the stock is 62.266% less volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.
-
Which is a Better Dividend Stock CAPR or LADX?
Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CAPR or LADX?
Capricor Therapeutics, Inc. quarterly revenues are --, which are larger than LadRx Corp. quarterly revenues of --. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than LadRx Corp.'s net income of -$719.3K. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 118.88x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CAPRCapricor Therapeutics, Inc.118.88x -- -- -$24.6M LADXLadRx Corp.-- 0.84x -- -$719.3K
-
Which has Higher Returns CAPR or PSTV?
Plus Therapeutics, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -316.61%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About CAPR or PSTV?
Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 74.27%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1778.42%. Given that Plus Therapeutics, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Capricor Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CAPRCapricor Therapeutics, Inc.8 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is CAPR or PSTV More Risky?
Capricor Therapeutics, Inc. has a beta of 0.377, which suggesting that the stock is 62.266% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock CAPR or PSTV?
Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CAPR or PSTV?
Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 118.88x versus 4.69x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CAPRCapricor Therapeutics, Inc.118.88x -- -- -$24.6M PSTVPlus Therapeutics, Inc.4.69x -- $1.4M -$4.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
